Sleep-wake disturbance in patients with brain tumors

Terri S Armstrong, Marcia Y Shade, Ghislain Breton, Mark R Gilbert, Anita Mahajan, Michael E Scheurer, Elizabeth Vera, Ann M Berger, Terri S Armstrong, Marcia Y Shade, Ghislain Breton, Mark R Gilbert, Anita Mahajan, Michael E Scheurer, Elizabeth Vera, Ann M Berger

Abstract

Sleep-wake disturbances are defined as perceived or actual alterations in sleep that result in impaired daytime functioning. Unlike other cancers, there is limited information about sleep-wake disturbances in adults with primary brain tumors throughout the illness trajectory. Sleep-wake disturbance is among the most severe and common symptoms reported by primary brain-tumor patients, particularly those undergoing radiation therapy. As with other cancers and neurologic illness, sleep-wake disturbance may also be clustered or related to other symptoms such as fatigue, depression, and cognitive impairment. There is increasing evidence for a genetic basis of normal sleep and sleep regulation in healthy adults. Specific mutations and single nucleotide variants have been reported to be associated with both fatigue and sleep-wake disorders, and both inflammation and alterations in circadian rhythms have been postulated to have a potential role. Guidelines for assessment and interventions have been developed, with cognitive behavioral therapy, exercise, and sleep hygiene demonstrating benefit in patients with other solid tumors. Further research is needed to identify risk and appropriate treatment in the brain-tumor patient population.

Keywords: brain tumor; hypersomnia; insomnia; radiation therapy; sleep-wake; symptoms.

© The Author(s) 2016. Published by Oxford University Press on behalf of the Society for Neuro-Oncology. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.

Figures

Fig. 1.
Fig. 1.
Assessment and management of sleep-wake disturbance in the primary brain tumor patient population.
Fig. 1.
Fig. 1.
Assessment and management of sleep-wake disturbance in the primary brain tumor patient population.

Source: PubMed

3
Sottoscrivi